Kangmei Pharmaceutical (600518) Fundamentals 2026 — Revenue Analysis | SniperIQ
Kangmei Pharmaceutical (600518) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥18.7B, trading at ¥1.35 on the SHH. This SniperIQ fundamentals page covers Kangmei Pharmaceutical's valuation, profitability (net margin -0.3%), revenue (¥5.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Kangmei Pharmaceutical's market cap?
Kangmei Pharmaceutical (600518) has a market capitalization of approximately ¥18.7B, trading at ¥1.35 on the SHH. Market cap moves with the live share price.
What is Kangmei Pharmaceutical's P/E ratio?
Kangmei Pharmaceutical's trailing twelve-month P/E ratio is not meaningful (negative or nil earnings), with a price-to-book (P/B) of 3.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Kangmei Pharmaceutical?
Kangmei Pharmaceutical runs a net profit margin of -0.3%, a gross margin of 19.7%, and an operating margin of -5.2%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Kangmei Pharmaceutical generate?
Kangmei Pharmaceutical reported revenue of ¥5.2B for fiscal year 2025, with net income of ¥10M and earnings per share (EPS) of 0.0007. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Kangmei Pharmaceutical pay a dividend?
Kangmei Pharmaceutical does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Kangmei Pharmaceutical financially healthy?
Kangmei Pharmaceutical carries a debt-to-equity ratio of 0.02x and a current ratio of 1.27x, with a market beta of 0.54. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Kangmei Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Kangmei Pharmaceutical (600518) the key facts are: market cap ¥18.7B, revenue ¥5.2B, 52-week range 1.16-2.27. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Kangmei Pharmaceutical's full fundamentals live
Get Kangmei Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.